Re: Morbidelli Author 504 Pdf Download
Outi Foote
We recently bought a new 5 axis scm morbidelli M200 Author using a pod and rail system and was curious if anyone knows if a machine like this can be run by fusion. We are currently using fusion to run our old 3 axis machine and it works well. Fusion is in many ways still in beta so I do not know if it is high powered enough to run a new 5 axis. I know it has some 5 axis features in the CAM side, but curious if anyone has been running 5 axis fusion in a production setting. The machine has a Xilog controller and is running a non standard version of g code. Any feedback regarding the matter would be great. Thanks for the help.
Thanks for posting! Fusion defiantly has the power to handle 5x toolpaths for this machine, and even output the xxl file needed to run it. If the pods/rails are positioned within the program, this is a bit more difficult, but still possible.
For this kind of machine, I would recommend contacting your local CAM partner to discuss the requirements. The contact details for the partners can be found here: -post-processor-forum/hsm-post-adjustments-needed-find-your-right-...
I don't have a good working post processor for the Morbidelli 5 axis. I got it running 3 axis only. The problem with these machines is that when you begin tilting the 5 axis head, the machine is moving very slow. I can help you with maestro 3D if you have any problems with it.
I do have a post processor for the Morbidelli M series (5axis). It has taken a lot of work to get it functioning properly. There is intellectual property that I am not allowed to share without charging for it. It has taken several thousand dollars of programming and testing to get it right. If you are interested in this successfully tested post, you can email me at stanley at evolvecabinets dot com.
To save content items to your account,please confirm that you agree to abide by our usage policies.If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.Find out more about saving content to Dropbox.
To save content items to your account,please confirm that you agree to abide by our usage policies.If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.Find out more about saving content to Google Drive.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Therapeutic proteins (including native, recombinant proteins, and monoclonal antibodies) have been used successfully for a wide variety of treatments including the restoration of native biomolecules activity, integration of non-present proteins, control of metabolic pathways, and even cancer (Pelegri-ODay et al., 2014). From a therapeutic perspective, they offer superior advantages over conventional drugs, such as being highly specific and providing complex functions, having a high biological activity, and less risk of side effects (Pisal et al., 2010). However, there are several limitations associated with their use (excluding to monoclonal antibodies), such as short half-life within the body, low solubility, physicochemical instability, susceptibility to proteolytic degradation, and immunogenicity (Pfister and Morbidelli, 2014). Protein modification has emerged as a strategy to overcome these challenges.
To obtain regulatory approval and successfully reach the market, therapeutic proteins must be manufactured under conditions that ensure their safety and efficacy. This is not a trivial process. Therapeutic proteins are generally produced using living cells or microorganisms (Lagass et al., 2017). Moreover, proteins need to maintain their three-dimensional structure to be biologically active, which involves not only the correct sequence of amino acids but also proper folding and specific post-translational modifications (Chaudhary et al., 2017). Since therapeutic proteins are synthesized using cell-based production systems, complex purification strategies are generally involved. Several contaminants including DNA, cell debris, endotoxins, host cell proteins, media components, and viruses must be removed. Additionally, protein modification increases the complexity of purification even further, as more impurities may be added to the process, such as unreacted protein, reagents, or multiple less functional isomers. Currently, most purification processes for modified therapeutic proteins are based on chromatographic techniques. This may be explained by its multiple advantages over other methods, such as having a high resolution and robustness, and presenting high recovery levels (Przybycien et al., 2004; Gottschalk et al., 2012). To obtain the highest yield and purity, selection of a specific chromatographic technique and optimization of operating conditions are essential.
Numerous previous reviews describe the history, types of reactions, and purification strategies used for modified therapeutic proteins (Pfister and Morbidelli, 2014; Jafari et al., 2017; Jiang et al., 2018; Ramos-de-la-Pea and Aguilar, 2020; Duivelshof et al., 2021). However, they focus mainly on modified therapeutic proteins that have not reached the market yet and are still under development. This review presents a critical analysis of the chromatography-based purification strategies exclusively for all modified therapeutic proteins that have obtained regulatory approval and are currently commercialized. Based on such analysis, this review provides a guide for the selection of chromatography-based purification processes for novel modified therapeutic proteins. The information of the purification processes was mainly obtained from patents, as a primary source, or from the original reports associated to the design of the biopharmaceutical. This work is divided by modification type: PEGylation, Fc-fusion, and lipidation, while glycosylation and albumin-fusion are discussed in a single section given the low number of biopharmaceuticals from these categories currently on market. Within each section, a brief introduction of the modification strategy is presented, followed by an analysis of the purification process parameters (i.e., chromatographic technique, stationary phase, elution mode, etc.). Afterwards, coagulation factor IX, the only therapeutic protein with three different modifications on the market, is presented as a case study to demonstrate how the modification greatly influences the development of chromatographic processes. Finally, the current challenges to develop more efficient chromatography-based purification processes are summarized.
PEGylation can be carried out using different strategies depending on the nature of the protein and desired application. The covalent attachment of PEG chains occurs at chemically reactive residues, often exposed at the surface of the protein, including lysine, cysteine, serine, histidine, arginine, tyrosine, threonine, aspartic acid, and glutamic acid; or at the N- and C-terminus. For this reaction to occur, the PEG chain must be functionalized at one end with an active group (activated PEG), which is chosen depending on the available residue(s) in the protein. It is worth mentioning that, prior to PEG conjugation, the protein must be already pure to increase the yield of the reaction (Pfister and Morbidelli, 2014; Ramos-de-la-Pea and Aguilar, 2020). Nevertheless, depending on the PEGylation reaction strategy, the products may include a heterogenous mixture of mono-, multi-PEGylated products (proteins with a varying number of attached PEG molecules), and/or positional isomers (proteins with the same number of PEG chains that differ from each other in the location of the PEG molecule). All of these differ in physicochemical and pharmaceutical properties (Swierczewska et al., 2015). Moreover, at the end of the PEGylation reaction unreacted PEG and native (unmodified) protein may still be present. PEGylated species and reactants are separated mainly by chromatography in its different operational modes (Figure 2).
General scheme for the purification of commercial PEGylated proteins by chromatography. One or more chromatographic operational modes are used to separate the desired PEGylated protein(s) from the PEGylation reaction mixture. IEX, ion exchange chromatography; HIC, hydrophobic interaction chromatography; SEC, size exclusion chromatography.
ADA, adenosine deaminase; AEX, anion exchange chromatography; CEX, cation exchange chromatography; CT, chromatographic technique; FF, fast flow; G-CSF, granulocyte colony stimulating factor; GH, growth hormone; HIC, hydrophobic interaction chromatography; HP, high performance; HR, high resolution; IFN, interferon; NA, information not available; SEC, size exclusion chromatography; TNF, tumor necrosis factor. Notice that IFN alfa-2b is approved for different treatments according to dosage and presentation form.
High resolution and purity can be obtained using IEX by choosing optimal operating conditions. These conditions are the operation mode (bind-elute or flow-through), elution mode (linear or step gradient), stationary phase, sample load, mobile phase (type, concentration, and pH), elution type (ionic or pH), elution buffer (type, concentration, and pH), gradient length, flow rate, and column dimensions (Ahamed et al., 2008). From the information available on purification processes for commercial PEGylated proteins, the operation mode and elution methods are highlighted. Most of commercial PEGylated proteins are purified using a linear gradient elution, with a bind-elute operation mode. A common method for protein elution in IEX is using a salt gradient. In IEX, protein adsorption is driven by electrostatic interactions between the stationary phase and the proteins (Shi et al., 2005). These interactions are in turn affected by the nature and concentration of salt (ionic strength) in the mobile phase. As the salt concentration increases, the retention of the protein decreases as a consequence of loss of electrostatic interactions (Staahlberg et al., 1991). Salt gradients generated by increasing sodium chloride (NaCl) concentration (in a range from 0 to 1 M) prevail the most in the purification processes of commercial proteins (Neulasta, Somavert, Krystexxa, Mircera, Cimzia, Plegridy, Adynovi, and Esperoct) (Table 1). Only for the case of PEG-intron (a 12 kDa-PEG interferon alfa-2b for chronic hepatitis C), the ionic strength of the mobile phase was modified by increasing the buffer components concentration (from 10 to 80 mM Na3PO4). The salt concentration range used to elute a PEGylated protein must be carefully selected. It will depend on the surface net charge of the protein and how it is affected by the modification. When the PEG chain slightly alters the surface net charge of the protein, it is desirable to use a narrow concentration range of NaCl. This can be seen in the purification process of PEG-epoetin beta (Mircera), where the column was equilibrated with 100 mM of NaCl and the PEGylated protein was eluted with 200 mM NaCl (Burg et al., 2011).
7fc3f7cf58